Presentations

Bearss DJ. Targeting MCL1 dependent cancers by CDK9 inhibition. Paper presented at: 9th International Conference on Leukemia and Hematologic Oncology; October 5-6, 2017; London, UK.

Warner SL. Targeting novel kinases in hematologic malignancies. Paper presented at: 9th International Conference on Leukemia and Hematologic Oncology; October 5-6, 2017; London, UK.

Bearss DJ. Sequential treatment of AML patients with alvocidib followed by cytarabine and mitoxantrone is highly effective through a mechanism dependent on MCL1 expression and functions. Paper presented at: International Conference on Leukemia and Hematologic Oncology; October 17-18, 2016; Rome, Italy.

Peterson P, Kim W, Haws H, et al. The ALK-2 inhibitor, TP-0184, demonstrates high distribution to the liver contributing to significant preclinical efficacy in mouse models of anemia of chronic disease. Blood. 2016;128(22):263.

Peterson P, Soh KK, Lee YS, et al. ALK2 inhibition via TP-0184 abrogates inflammation-induced hepcidin expression and is a potential therapeutic for anemia of chronic disease. Blood. 2015;126(23):273.

Soh KK, Bahr BL, Bearss JJ, et al. Inhibition of Axl kinase reverses the mesenchymal phenotype in leukemia cells through the disruption of retinoic acid signaling. Blood. 2015;126(23):3253.

Pierceall WE, Warner SL, Lena RJ, et al. Bcl-xL dependence predicts response to alvocidib in chronic lymphocytic leukemia patients [AACR abstract 907]. Cancer Res. 2014;74(19)(suppl):907.

Anderson M, Ober A, Mollard A, et al. Inhibition of the tyrosine kinase receptor Axl blocks cell invasion and promotes apoptosis in pancreatic cancer cells [AACR abstract 5543]. Cancer Res. 2013;73(8)(suppl):5543.

Bearss DJ, Bahr B, Call L, Stephans BJ, Warner SL. Novel series of metabolic activators of PKM2 alter oncogene-meditated changes in tumor cell growth and metabolism. Paper presented at: 246th National Meeting of American Chemical Society (ACS); September 8-12, 2013; Indianapolis, IN. Abstract 204.

Cardnell R, Diao L, Wang J, et al. An epithelial-mesenchymal transition (EMT) gene signature to predict resistance to EGFR inhibition and AXL identification as a therapeutic target in head and neck squamous cell carcinoma [ASCO abstract 6011]. J Clin Oncol. 2013;31(15)(suppl):6011.

Carpenter KJ, Brog R, Moreno C, et al. Small molecule inhibitors of PIM kinases as potential treatments for urothelial carcinomas [AACR abstract 2174]. Cancer Res. 2013;73(8)(suppl):2174.

Faris M, Malyankar UM, Tam V, et al. Small molecule inhibitor of the BTK pathway disrupts BCR signaling and demonstrates antitumor efficacy in a xenograft model [AACR abstract LB-303]. Cancer Res. 2013;73(8)(suppl):LB-303.

Flory J, Brog R, Meng LY, et al. Overexpression of Nek2 promotes bortezomib resistance in multiple myeloma cells [AACR abstract 3391]. Cancer Res. 2013;73(8)(suppl):3391.

Stephens BJ, Mollard A, Meng L, Bearss DJ, Warner SL. TP-0413 is a dual-specific inhibitor against Jak2 and Alk2 with therapeutic potential for treating anemia of chronic disease [AACR abstract 904]. Cancer Res. 2013;73(8)(suppl):904.

Walker B, Venkataswamy S, Warner S, et al. Mechanisms of sensitivity to treatment with the PDK1 inhibitors HCI-1680 and HCI-1708 [AACR abstract 4413]. Cancer Res. 2013;73(8)(suppl):4413.

Bahr BL, Stevens J, Squire S, et al. A novel series of metabolic activators of PKM2 alter oncogene-meditated changes in tumor cell metabolism [AACR abstract 1875]. Cancer Res. 2013;73(8)(suppl):1875.

Albertson DJ, Bearss JJ, Bearss DJ, Tripp S, Liu T. Proviral integration site Moloney murine leukemia virus (PIM) expression in urothelial carcinoma [abstract 791]. Paper presented at: 102nd Annual Meeting of United States and Canadian Academy of Pathology (USCAP); March 2-8, 2013; Baltimore, MD.

Colman H, Oddou MP, Mollard A, et al. A multi-targeted kinase inhibitor (HCI-2084) potently inhibits the Aurora, Axl, and STAT3 pathways and causes cell cycle arrest and apoptosis in GBM stem-like cells [SNO abstract ET-47]. Neuro Oncol. 2012;14(suppl 6):vi34-vi35.

Meng L, Warner SL, Mollard M, Vankayalapati H, Sharma S, Bearss DJ. Inhibition of Nek2 by novel small molecules affects proteasome activity [AACR abstract 2776]. Cancer Res. 2012;72(8)(suppl):2776.

Verma A, Frazer JK, Trakhimets A, et al. A novel dual AXL/Mertk and Aurora kinase inhibitor active against T cell acute lymphoblastic leukemia [ASH abstract 1519]. Blood. 2011;118(21):1519.

Call LT, Mollard A, Wade ML, et al. Targeting the Axl tyrosine kinase receptor in pancreatic cancer [AACR abstract 2577]. Cancer Res. 2011;71(8)(suppl):2577.

Mollard A, Warner SL, Call L, et al. Homology structure-based design, synthesis and biological evaluation of a series of novel Axl and Mer kinase inhibitors [AACR abstract 3609]. Cancer Res. 2011;71(8)(suppl):3609.

Sharma S, Venkataswamy S, Warner SL, Call LT, Bearss DJ, Vankayalapati H. Fragment-based design, synthesis and biological evaluation of a series of novel PDK1 inhibitors [AACR abstract 1368]. Cancer Res. 2011;71(8)(suppl):1368.

  


Targeted therapy is at the heart of
our pipeline.

Pipeline >

See why we’re investigating MCL-1
as a potential apoptosis inhibitor.

MCL-1 >

Learn about our clinical trials
currently underway.

CLINICAL TRIALS >